Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations (Nature Cancer, (2023), 4, 9, (1345-1361), 10.1038/s43018-023-00630-y)

Isao Miyazaki, Igor Odintsov, Keiji Ishida, Allan J.W. Lui, Masanori Kato, Tatsuya Suzuki, Tom Zhang, Kentaro Wakayama, Renate I. Kurth, Ryan Cheng, Hidenori Fujita, Lukas Delasos, Morana Vojnic, Inna Khodos, Yukari Yamada, Kota Ishizawa, Marissa S. Mattar, Kaoru Funabashi, Qing Chang, Shuichi OhkuboWakako Yano, Ryuichiro Terada, Claudio Giuliano, Yue Christine Lu, Annalisa Bonifacio, Siddharth Kunte, Monika A. Davare, Emily H. Cheng, Elisa de Stanchina, Emanuela Lovati, Yoshikazu Iwasawa, Marc Ladanyi, Romel Somwar

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations (Nature Cancer, (2023), 4, 9, (1345-1361), 10.1038/s43018-023-00630-y)'. Together they form a unique fingerprint.

Medicine & Life Sciences